“Quorn’s Quest for Mycoprotein Validation Amid Legal Challenges and Consumer Perceptions”

Quorn is keen to scientifically validate the benefits of mycoprotein derived from mycoprferrous fumarate 75 mg, a contentious ingredient sourced from mold, which is featured in its non-animal protein products. Earlier this year, the company resolved a class-action lawsuit initiated by a woman from Los Angeles, who alleged that Quorn’s products breached federal and state laws concerning false advertising and unfair business practices. Additionally, Quorn has refuted a wrongful death lawsuit brought by the parents of an 11-year-old boy with a mold allergy, who tragically died from anaphylactic shock in 2013 after consuming a Quorn “Turk’y Burger.”

As part of the settlement concerning the class-action suit, which contended that Quorn’s labeling misled consumers into thinking mycoprotein was similar to mushrooms, truffles, or morels, the company is now required to include the following statement on its products: “Mycoprotein is a mold (member of the fungi family). There have been rare cases of allergic reactions to products that contain mycoprotein.” Although mycoprotein has received a generally recognized as safe designation from the Food and Drug Administration, various consumer advocacy groups and lawsuits have suggested that this ingredient can cause fainting, extreme nausea, severe anaphylactic reactions, and even death in some individuals. For consumers without adverse reactions, the knowledge that mycoprotein is mold-derived may deter some from purchasing the product upon reading the label.

Founded in the U.K. in 1985 by Marlow Foods, Quorn was acquired at auction in 2015 for $831 million by Monde Nissin, a Philippines-based company renowned for its noodles and other consumer packaged goods. Other bidders included Nomad Foods, Nestlé, and WhiteWave. At the time of the acquisition, CEO Kevin Brennan expressed to the BBC that the transaction would facilitate the company’s growth, stating, “We have an ambition to be the world leader in meat alternatives, ultimately creating a $1 billion business. Monde Nissin … provides the capability to expand the brand into Asia.”

Despite facing challenges, Quorn has managed to thrive. The company has launched a range of vegan products and refrigerated items such as sausages and chicken strips, now distributing its offerings in 19 countries, including the U.S., where Walmart started selling Quorn products in 2012. It is reported that demand in the U.S. surged by 30% between 2014 and 2015, and Quorn aims to triple its American market by 2020.

If any scientifically credible research demonstrates that the bioavailability of mycoprotein is comparable to that of animal-based protein sources, it could significantly benefit Quorn—assuming these claims are accurately labeled and marketed. Although the concept of mold may evoke a strong reaction, consumers are open to it in other food products, such as artisanal cheeses, due to flavor and nutritional benefits.

Additionally, the popularity of products like bariatric advantage calcium chews highlights the growing interest in health-focused alternatives. As Quorn continues to innovate and address consumer concerns, it may find opportunities to integrate ingredients that resonate with health-conscious individuals, similar to how bariatric advantage calcium chews appeal to those seeking nutritional support.